Novaliq’s NovaTears®+Omega-3 Approved in Europe for the Enhanced Treatment of Evaporative Dry Eye Disease

Heidelberg, Germany – December 6, 2017 – Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced the European registration of NovaTears®+Omega-3 for the enhanced treatment of the signs and symptoms of evaporative dry eye disease (DED).

Details

Novaliq announces first patient randomized in its ESSENCE phase 2b/3 trial of CyclASol® for the treatment of the signs and symptoms of dry eye disease

Heidelberg, Germany – November 9, 2017 – Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced that it has begun randomization of patients in its ESSENCE Phase 2b/3 clinical trial that will evaluate CyclASol® for the treatment of the signs…

Details

Novaliq’s NovaTears® treatment for evaporative dry eye disease launches in New Zealand and receives registrational approval in Australia

Heidelberg, Germany – October 30, 2017 – Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced the launch of NovaTears® in New Zealand and registrational approval in Australia. According to McCarty, the prevalence of dry eye disease (DED) is approximately…

Details

German Ophthalmological Society honors Uta Gehlsen with prestigious scientific award for her research on the use of semifluorinated alkanes in dry eye treatment

Heidelberg, Germany – October 2, 2017 – The German Ophthalmological Society (DOG) presented Uta Gehlsen, PhD, Ocular Surface Group, Department of Ophthalmology, University of Cologne, with the “Dry Eye and Blepharitis/MGD” Award for her research related to the use of a semifluorinated alkane (SFA F4H5) as a novel carrier for cyclosporine A for the topical…

Details